35995-55-2

Upstream product

• 14690-00-7 2-O-benzylglycerol 
• 100-39-0 benzyl bromide 
• 3132-64-7 1,2-Epoxy-3-bromopropane 
• 558-13-4 carbon tetrabromide 

Downstream Products

• 54166-15-3 diethyl 3-(benzyloxy)cyclobutane-1,1-dicarboxylate 
• 917887-34-4 1-methylsulfinyl-1-methylthio-3-benzyloxycyclobutane 
• 4934-97-8 diisoamyl 3-benzyloxycyclobutane-1,1-dicarboxylate 
• 30830-27-4 3-benzyloxy cyclobutanone 
• 1181816-13-6 3-(benzyloxy)-1-cyanocyclobutane carboxylic acid ethyl ester 
• 1369321-21-0 [(μ-SCH2)2CH(OCH2Ph)]Fe2(CO)6 
• 100058-61-5 3-(phenylmethoxy)cyclobutan-1-ol 
• 1581683-63-7 5-(phenylmethoxy)-2-[3-(phenylmethoxy)cyclobutoxy]pyrimidine 
• 1181816-14-7 3-(benzyloxy)-1-(hydroxymethyl)cyclobutanecarbonitrile 
• 1603067-34-0 3-(benzyloxy)spiro[cyclobutane-1,3'-indolin]-2'-one 
• 4934-98-9 methylester of 3-benzyloxycyclobutane-1-carboxylic acid 
• 1417818-85-9 methyl O-[trans-3-(benzyloxy)cyclobutyl]-N-(tert-butoxycarbonyl)-D-tyrosine 
• 1262278-69-2 methyl O-[trans-3-(benzyloxy)cyclobutyl]-N-(tert-butoxycarbonyl)-L-tyrosine 

Relevant academic research and scientific papers

Synthesis of cationic cardiolipin analogues

An approach was developed to synthesize a new class of cationic cardiolipin analogues containing two quaternary ammonium groups with tetra alkyl groups retaining "glycerol" moiety, the central core of the molecule. Cationic cardiolipin analogues were modified via introduction of either two or four oxyethylene groups to enhance the solubility in polar solvents. These newly synthesized cationic cardiolipin analogues can be applied to a broad range of drug delivery systems such as transfection reagents.

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS

Compound (I), deuterated derivatives, and pharmaceutically acceptable salts of any of the foregoing are disclosed. Methods of treating cystic fibrosis using these compounds are also disclosed.

Novel CDK inhibitory compounds, preparation method thereof, pharmaceutical composition for use in preventing or treating CDK relating diseases containing the same as an active ingredient

The present invention relates to a novel CDK inhibitory compound, a method for manufacturing the same, and a pharmaceutical composition for preventing or treating a CDK-related disease containing the compound as an active ingredient. The novel CDK inhibit

Hydroxypurine compound and use thereof

The invention discloses a hydroxypurine compound and a use of the hydroxypurine compound as a PDE2 or TNFa inhibitor and concretely discloses a compound shown in the formula (I) and its tautomer or pharmaceutically acceptable salt.

AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, R1, R2, R3, R7 and n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-II.

TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS

Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. In addition, species of tricyclic gyrase inhibitors compounds are also disclosed herein. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

RSV ANTIVIRAL COMPOUNDS

Inhibitors of RSV replication of formula RI including stereochemically isomeric forms, and salts or solvates thereof, wherein R22, W, Q, V, Z p,s,and Het have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other RSV inhibitors, in RSV therapy.

PRECURSOR COMPOUNDS AND METHODS FOR MAKING SAME

The present invention relates to a method of obtaining radiopharmaceutical precursors, and in particular precursors to protected amino acid derivatives, which are used as precursors for production of radiolabelled amino acids for use in in vivo imaging procedures, such as positron emission tomography (PET).

Investigations into the synthesis, radiofluorination and conjugation of a new [18F]fluorocyclobutyl prosthetic group and its in vitro stability using a tyrosine model system

The [18F]fluorocyclobutyl group has the potential to be a metabolically stable prosthetic group for PET tracers. The synthesis of the radiolabeling precursor cis-cyclobutane-1,3-diyl bis(toluene-4-sulfonate) 8 was obtained from epibromohydrin i

AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS

The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.